当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Moges Woldemeskel
Renal Cell Carcinoma (RCC) is the most common primary renal neoplasm in humans and domestic animals such as dogs, cats and horses. Various subtypes are recognized in both humans and animals. Advances in biomedical sciences have developed hitherto unprecedented extraordinary cancer therapeutic options varying from sophisticated surgery to immunotherapy and gene therapy. Treatment regimens employed, response to treatments and prognosis vary based on the subtypes of RCC, degree of malignancy, metastasis and stage of the neoplasm. Surgery is the main treatment for most RCCs. Drug resistance has long been a challenge in cancer treatment. New insights in cancer treatment such as molecular targeted therapy including nano-medicine against chemo-resistance are among the contemporary developments targeting cancers. This mini review highlights on the occurrence and significance of RCC in humans and animals, briefly summarizes the various subtypes reported and the treatment regimens executed.